NeoPrediX – a predictive analytics company focused on neonatal, maternal, and perinatal health – announced an investment from Springhood Ventures. This deal will further accelerate the development and deployment of NeoPredix’s innovative solutions aimed at improving outcomes for newborns worldwide.
Springhood Ventures, a VC firm dedicated exclusively to children’s health, backs early-stage companies focused on improving health outcomes during the first years of life. And the firm aims to scale evidence-based clinical solutions for children by backing passionate entrepreneurs advancing groundbreaking science and technology with strong commercial potential. This investment exemplifies a commitment to fostering innovations in neonatal care, helping startups navigate the journey from concept to impactful solutions.
This deal marks a significant milestone for companies as they continue to advance their shared mission of improving neonatal health by delivering cutting-edge and evidence-based technology globally.
KEY QUOTES:
“NeoPrediX is at the forefront of utilizing predictive analytics to make a real difference in the lives of newborns. This investment from Springhood Ventures not only validates our approach but also enables us to scale our efforts and bring our solutions to the neonatal community faster. We are grateful for Springhood’s support and partnership as we work together to ensure that every child has the best possible start in life.”
-Thorsten Waloschek, CEO of NeoPrediX
“At Springhood, we are driven by our mission to support innovations that have the potential to transform children’s health. NeoPrediX is doing exceptional work in neonatal care, and we are excited to help them expand their portfolio. By investing in companies like NeoPrediX, we are not only contributing to better health outcomes for children but also creating exceptional value for our investors.”
-John Parker, Founder and Managing Partner of Springhood Ventures
